No retraction, correction or concern found when last checked on Oct 23, 2026.

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain

Deanna Kerrigan, Andrea Mantsios, Miguel Gorgolas and 9 more (opens in a new tab)

PLOS ONE · 2018 · CC BY

doi:10.1371/journal.pone.0190487 (opens in a new tab)

Abstract

Challenges with adherence to daily oral antiretroviral therapy (ART) among people living with HIV (PLHIV) have stimulated development of injectable long-acting (LA) regimens. We conducted 39 in-depth interviews with participants and providers in a Phase IIb study (LATTE-2) evaluating an injectable LA regimen in the U.S. and Spain. Interviews exploring participant and provider attitudes and experiences with LA versus oral ART were audiotaped, transcribed and analyzed using thematic content analysis. Participants described the convenience of LA injections versus daily pills and emotional benefits such as minimized potential for HIV disclosure and eliminating the “daily reminder of living with HIV.” Providers recognized benefits but cautioned that LA candidates still need to adhere to clinic visits for injections and raised questions around ongoing clinical management. LA was seen as preferable to daily oral ART among PLHIV. Further research is needed regarding appropriate candidates, including with women and “non-adherent” populations across settings.

References 42

1.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Fact Sheet 2016. Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf.
Not in our library
2.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Update 2016. Available from: http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf.
Not in our library
3.
Joint United Nations Programme on HIV/AIDS (UNAIDS). The Gap Report 2014. Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf.
Not in our library
4.
Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine. 1998;338(13):853–60
Not in our library10.1056/nejm199803263381301 (opens in a new tab)
5.
Li TS, Tubiana R, Katlama C, Calvez V, Mohand HA, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. The Lancet. 1998;351(9117):1682–6.
Not in our library10.1016/s0140-6736(97)10291-4 (opens in a new tab)
6.
Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. New England Journal of Medicine. 2000;342(13):921–9
Not in our library10.1056/nejm200003303421303 (opens in a new tab)
7.
Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2005;40(1):96–101.
Not in our library10.1097/01.qai.0000157389.78374.45 (opens in a new tab)
8.
Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. The Lancet. 2010;375(9731):2092–8.
Not in our library10.1016/s0140-6736(10)60705-2 (opens in a new tab)
9.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011;365(6):493–505
Not in our library10.1056/nejmoa1105243 (opens in a new tab)
10.
Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Current Opinion in HIV and AIDS. 2012;7(2):99
Not in our library10.1097/coh.0b013e32834f5cf2 (opens in a new tab)
11.
Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. The Lancet infectious diseases. 2014;14(4):281–90
Not in our library10.1016/s1473-3099(13)70692-3 (opens in a new tab)
12.
Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell M-L. High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966–71
Not in our library10.1126/science.1228160 (opens in a new tab)
13.
Decreases in Community Viral Load Are Accompanied by Reductions in New HIV Infections in San Francisco · 2010
No notice
14.
Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. The Lancet. 2010;376(9740):532–9.
Not in our library10.1016/s0140-6736(10)60936-1 (opens in a new tab)
15.
Beer L, Heffelfinger J, Frazier E, Mattson C, Roter B, Barash E, et al. Use of and adherence to antiretroviral therapy in a large US sample of HIV-infected adults in care, 2007–2008. The open AIDS journal. 2012;6(1).
Not in our library10.2174/1874613601206010213 (opens in a new tab)
16.
Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators · 2006
No notice
17.
Chesney MA. Factors affecting adherence to antiretroviral therapy. Clinical Infectious Diseases. 2000;30(Supplement 2):S171–S6.
Not in our library10.1086/313849 (opens in a new tab)
18.
Kagee A, Remien RH, Berkman A, Hoffman S, Campos L, Swartz L. Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Global public health. 2011;6(1):83–97
Not in our library10.1080/17441691003796387 (opens in a new tab)
19.
Reda AA, Biadgilign S. Determinants of Adherence to Antiretroviral Therapy among HIV-Infected Patients in Africa. AIDS Research and Treatment. 2012;2012:574656
Not in our library10.1155/2012/574656 (opens in a new tab)
20.
Gross IM, Hosek S, Richards MH, Fernandez MI. Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV. AIDS Patient Care and STDs. 2016;30(7):324–38
Not in our library10.1089/apc.2015.0351 (opens in a new tab)
21.
Mellins CA, Kang E, Leu C-S, Havens JF, Chesney MA. Longitudinal study of mental health and psychosocial predictors of medical treatment adherence in mothers living with HIV disease. AIDS Patient Care and STDs. 2003;17(8):407–16
Not in our library10.1089/108729103322277420 (opens in a new tab)
22.
Golin CE, Liu H, Hays RD, Miller LG, Beck CK, Ickovics J, et al. A prospective study of predictors of adherence to combination antiretroviral medication. Journal of general internal medicine. 2002;17(10):756–65
Not in our library10.1046/j.1525-1497.2002.11214.x (opens in a new tab)
23.
Kacanek D, Angelidou K, Williams PL, Chernoff M, Gadow KD, Nachman S, et al. Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study. AIDS. 2015;29(10):1227–37
Not in our library10.1097/qad.0000000000000697 (opens in a new tab)
24.
Murray LK, Semrau K, McCurley E, Thea DM, Scott N, Mwiya M, et al. Barriers to acceptance and adherence of antiretroviral therapy in urban Zambian women: a qualitative study. AIDS care. 2009;21(1):78
Not in our library10.1080/09540120802032643 (opens in a new tab)
25.
Impact of HIV‐related stigma on treatment adherence: systematic review and meta‐synthesis · 2013
No notice
26.
Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care & STDs. 2006;20(5):359–68.
Not in our library10.1089/apc.2006.20.359 (opens in a new tab)
27.
Andrews CD, Heneine W. Cabotegravir long-acting for HIV-1 prevention. Current Opinion in HIV and AIDS. 2015;10(4):258–63
Not in our library10.1097/coh.0000000000000161 (opens in a new tab)
28.
Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment. Current Opinion in HIV and AIDS. 2015;10(4):246–52
Not in our library10.1097/coh.0000000000000169 (opens in a new tab)
29.
Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Current Opinion in HIV and AIDS. 2013;8(6):565–71
Not in our library10.1097/coh.0000000000000002 (opens in a new tab)
30.
Margolis D, Podzamczer D, Stellbrink H, Lutz T, Angel J, Richmond G, et al., editors. Cabotegravir + rilpivirine as long-acting maintenance therapy: LATTE-2 week 48 results 21st International AIDS Conference (AIDS 2016); 2016; Durban.
Not in our library
31.
Margolis DA, Gonzalez-Garcia J, Stellbrink H-J, Eron J, Yazdanpanah Y, Griffith SK, et al., editors. Cabotegravir+ rilpivirine as long-acting maintenance therapy: LATTE-2 week 32 results. Conference on Retroviruses and Opportunistic Infections (CROI); 2016; Boston.
Not in our library
32.
Guest G, Bunce A, Johnson L. How many interviews are enough? Field Methods. 2006;18(1):59–82.
Not in our library
33.
Patton MQ. Qualitative Research and Evaluation Methods (3rd Edition). United States: Sage Publications; 2002.
Not in our library
34.
Scientific Software Development GmbH. ATLAS.ti 1.0.50 ed. Eden Prairie, MN,2013.
Not in our library
35.
Pope C, Ziebland S, Mays N. Analysing qualitative data. BMJ: British Medical Journal. 2000;320(7227):114–6.
Not in our library10.1136/bmj.320.7227.114 (opens in a new tab)
36.
Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115–25.
Not in our library10.2147/ppa.s10330 (opens in a new tab)
37.
Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials · 2014
No notice
38.
Parienti J-J, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clinical Infectious Diseases. 2009;48(4):484–8
Not in our library10.1086/596482 (opens in a new tab)
39.
Robbins RN, Spector AY, Mellins CA, Remien RH. Optimizing ART Adherence: Update for HIV Treatment and Prevention. Current HIV/AIDS reports. 2014;11(4):423–33
Not in our library10.1007/s11904-014-0229-5 (opens in a new tab)
40.
Ware NC, Wyatt MA, Tugenberg T. Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS. AIDS Care. 2006;18(8):904–10
Not in our library10.1080/09540120500330554 (opens in a new tab)

All 42 references

Cited by papers we hold 3

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.